Legacy Housing Corporation Reports Third Quarter 2024 Financial Results BEDFORD, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (“Legacy” or the “Company,” NASDAQ: LEGH) today announced its financial results for the third quarter ended September 30, 2024. Financial Highlights Net revenue for the third quarter of 2024 was $44.3 million, a decrease of 11.4% from the third quarter of 2023.Income from operations for the third quarter of 2024 was $15.3 million, a decrease of 19.4% from the third quarter of 2023.Net income for the third quarter of 2024 was $15.8 million, ...
Nkarta to Participate in an Upcoming Investor Conference SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: Stifel 2024 Healthcare ConferenceNovember 19, 202410:55 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinica...
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025No further NKX019 development in lymphoma planned Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases Cash balance of $405.3 million on September 30, 2024, including cash, cash equivalents and investments,...
Legacy Housing Corporation Announces Timing of Third Quarter 2024 Earnings Release and Conference Call BEDFORD, Texas, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (“Legacy” or the “Company”, NASDAQ: LEGH) will release its financial results for the third quarter ended September 30, 2024, after markets close on Tuesday, November 12, 2024. The Company will then host a conference call at 10:00 a.m. Central Time on Wednesday, November 13, 2024. To access the conference call, please pre-register using this . Registrants will receive confirmation with dial-in details. A replay...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Nkarta to Participate in Upcoming Investor Conference SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 10, 202412:30 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About Nk...
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-spons...
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage bio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.